Core Laboratories N.V. cash flow to debt ratio of 22.67% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Core Laboratories N.V.'s free cash flow has decreased 47.91% from $43.36M last year to $22.59M, signaling decreasing performance

Core Laboratories N.V.'s debt to equity ratio is 0.61, which means that the company's assets are unhealthy financed, signaling financial risk.

Core Laboratories N.V.'s debt has decreased relative to shareholder equity from 0.71 last year to 0.61 today, signaling strengthened financials

Core Laboratories N.V. has a net debt to EBITDA ratio of 1.99x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Core Laboratories N.V.'s interest coverage ratio of 4.37 indicates that earnings with good margin can cover interest payments on company debt

Core Laboratories N.V.'s profit margin has decreased (21.74%) in the last year from 5.99% to 4.69%, signaling decreasing performance

Core Laboratories N.V.'s short-term assets of $214.66M exceed its short-term liabilities of $106.02M

Core Laboratories N.V.'s return on assets of 4.15% is lower than the 5.00% threshold, indicating inefficient asset utilization

Core Laboratories N.V.'s return on equity of 9.03%, is lower than 15.00%, indicating bad performance

Core Laboratories N.V.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Core Laboratories N.V. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Core Laboratories N.V. has positive free cash flow, indicating the company generates cash after capital expenditures

Core Laboratories N.V. has a free cash flow yield of 4.01%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Core Laboratories N.V.'s yearly earnings has decreased 5.51% since last year from $31.40M to $29.67M, signaling decreasing performance

Core Laboratories N.V.'s yearly revenue has increased 0.51% since last year from $523.85M to $526.52M, signaling increasing performance

ROIC 6.48% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Core Laboratories N.V.'s 3-year revenue CAGR of 2.44% is positive, indicating growing revenue over the past 3 years

Core Laboratories N.V. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Core Laboratories N.V. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Core Laboratories N.V. has insufficient data to evaluate this check.

Core Laboratories N.V. has an earnings yield of 4.25%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Core Laboratories N.V. is overvalued relative to its fair value price of 5.67 based on EBITDA multiple model

Core Laboratories N.V. has an EV/EBITDA ratio of 9.91x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Core Laboratories N.V. is overvalued relative to its fair value price of 9.53 based on Earnings Fair Value model

Core Laboratories N.V. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Core Laboratories N.V. has a price-to-book ratio of 2.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Core Laboratories N.V. has a price-to-sales ratio of 1.10x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue